STOP-CA
2023
Statins TO Prevent the Cardiotoxicity From Anthracyclines
In 300 patients with lymphoma scheduled for anthracycline-based chemotherapy, atorvastatin 40 mg daily for 12 months reduced the proportion of patients with an ejection-fraction decline of at least 10 % to below 55 % compared with placebo.
Result
Efficacy: Proportion with an absolute LVEF decline of ≥10 % to a final value below 55 % at 12 monthsodds ratio for placebo 2.9 (95% CI 1.4-6.4) · P = 0.002
Below 1 favours placebo, above 1 favours atorvastatin 40 mg daily for 12 months.
- Absolute difference
- 13 points
- NNT
- 8
Absolute difference and NNT are derived from the event rates.
Also reported: Adjudicated heart failure 3 % vs 6 % (p=0.26; not significant).
- Subtopic
- Statin cardioprotection
- Design
- Double-blind, placebo-controlled RCT
- Relevance
- Important: one of several pillars.
- Source
- Neilan TG, Quinaglia T, Onoue T, et al. JAMA. 2023;330(6):528-536.doi 10.1001/jama.2023.11887
Discussion & critique
The endpoint is an echocardiographic surrogate; the trial was not powered for heart failure, and clinical heart failure did not differ between arms. It is the largest positive statin trial in cardio-oncology and provides the randomised basis for statin cardioprotection in high-risk patients receiving anthracyclines.